For its part, Momenta shares are up about 70% into the low-$52s, close to that $52.50 a share offer it received from J&J in the all-cash deal.
Johnson & Johnson investors aren't sweating the deal, either. The stock is up about 0.6% on the day, as some analysts have even made the case that the deal undervalues Momenta.
The deal is expected to close in the second half of 2020 and will be used to bolster Johnson & Johnson’s autoimmune treatments.
All in all, the stock has been setting up attractively on the charts and the Momenta deal, at least so far, isn’t don’t anything to derail the technicals.
Trading Johnson & Johnson Stock
J&J stock topped out near $152.50 in February, before tumbling toward $100 a month later. When shares rebounded, we had a near-perfect V-shaped recovery. Since then though, the stock has been consolidating.
Even though Johnson & Johnson stock temporarily cleared the prior high, this $152.50 area continues to act as resistance. It rejected the stock in May and July, although shares are gaining momentum once again here in August.
Johnson & Johnson stock is above all three of its major moving averages and is riding uptrend support higher (blue line). If it can clear the July high at $151.67, then it puts the $152.50 mark in play.
Bulls are looking for a breakout over this mark, putting the all-time high in play near $156, followed by the 123.6% extension up near $163. If all of that plays out, we’ll need to re-evaluate the stock before getting too far ahead of our skis.
On the downside, look for a break of uptrend support. Below puts the $143 to $144 area in play. That’s where the 78.6% retracement and July 31st low come into play. Below that area and the 200-day moving average is on watch, along with the June low near $137.50.